220 related articles for article (PubMed ID: 25534747)
1. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
Izquierdo I; Borja J; Rovira S; Pelagio P; Torres F; Cebrecos J; García-Rafanell J
Arzneimittelforschung; 2010; 60(1):36-41. PubMed ID: 20184225
[TBL] [Abstract][Full Text] [Related]
3. Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
Ge J; Ding LK; Yang J; Jia YY; Lu CT; Ding Y; Song Y; Song W; Wen AD
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):272-6. PubMed ID: 25546165
[TBL] [Abstract][Full Text] [Related]
4. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Yun HY; Baek IH; Kwon KI; Yoon YR
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1471-9. PubMed ID: 22098139
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers.
Quetglas EG; Campanero MA; Sádaba B; Escolar M; Azanza JR
Arzneimittelforschung; 2008; 58(6):283-7. PubMed ID: 18677970
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.
Ramis J; Mis R; Forn J; Torrent J; Gorina E; Jané F
Eur J Drug Metab Pharmacokinet; 1991; 16(4):269-73. PubMed ID: 1823870
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
8. Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.
Valle M; Barbanoj MJ; Donner A; Izquierdo I; Herranz U; Klein N; Eichler HG; Müller M; Brunner M
Eur J Clin Pharmacol; 2005 Apr; 61(2):103-11. PubMed ID: 15711832
[TBL] [Abstract][Full Text] [Related]
9. Platelet antiaggregatory effect of triflusal in human whole blood.
de la Cruz JP; Pavia J; Bellido I; González MC; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1988 Apr; 10(4):273-7. PubMed ID: 3386335
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
[TBL] [Abstract][Full Text] [Related]
11. Semi-mechanistic modelling and simulation of inhibition of platelet aggregation by antiplatelet agents.
Yun HY; Kang W; Lee BY; Park S; Yoon YR; Yeul Ma J; Kwon KI
Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):352-9. PubMed ID: 24612881
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
Wang M; Zhang Q; Huang M; Zong S; Hua W; Zhou W
Drug Res (Stuttg); 2014 May; 64(5):263-8. PubMed ID: 24105106
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
[TBL] [Abstract][Full Text] [Related]
14. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.
De La Cruz JP; Villalobos MA; García PJ; Smith-Agreda JM; Sánchez de la Cuesta F
Eur J Clin Pharmacol; 1995; 47(6):497-502. PubMed ID: 7768251
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients.
Lee J; Hwang Y; Kang W; Seong SJ; Lim MS; Lee HW; Yim DS; Sohn DR; Han S; Yoon YR
J Clin Pharmacol; 2012 Jul; 52(7):985-95. PubMed ID: 21617016
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of triflusal after single and repeated doses in man.
Ramis J; Torrent J; Mis R; Conte L; Barbanoj MJ; Jané J; Forn J
Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):344-9. PubMed ID: 2272716
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of triflusal and its main metabolite in rats and dogs.
Ramis J; Mis R; Forn J
Eur J Drug Metab Pharmacokinet; 1991; 16(4):261-8. PubMed ID: 1823869
[TBL] [Abstract][Full Text] [Related]
18. 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation.
Bayón Y; Alonso A; Sánchez Crespo M
Br J Pharmacol; 1999 Mar; 126(6):1359-66. PubMed ID: 10217529
[TBL] [Abstract][Full Text] [Related]
19. Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.
Mis R; Ramis J; Conte L; Forn J
Eur J Clin Pharmacol; 1992; 42(2):175-9. PubMed ID: 1618249
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids.
González-Correa JA; Arrebola MM; Ureña IM; Ruiz-Villafranca D; Muñoz-Marín J; Guerrero A; Sánchez de la Cuesta F; De La Cruz JP
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jan; 371(1):81-8. PubMed ID: 15602657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
